Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Ibrutinib

Ibrutinib (November 2019)

This factsheet describes the use of ibrutinib for the treatment of certain types of lymphoma (relapsed or refractory mantle cell lymphoma; relapsed or refractory CLL; CLL and a 17p deletion). It covers what ibrutinib is, who can have it and who cannnot, its benefits, how it is given, side effects and precautions while being treated.

Author(s)
Lymphoma Action
Place of publication
Aylesbury
Publisher
Date of publication
November 2019
Pages
9pp
Format
Factsheet
Language
English
Flesch readability score
51.7
Download this resource
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm